EG-VEGF/Prokineticin 2 receptor antagonists
OA: closed
AI-generated summary
This patent describes compositions containing EG-VEGF nucleic acids, antibodies, or antisense agents to treat endometriosis and carcinoma, alongside methods for detecting uterine receptivity and identifying EG-VEGF receptor antagonists.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Treatment and prevention of endometrial disease, e.g. endometriosis or carcinoma, by inhibiting endocrine gland vascular endothelial growth factor, also diagnosis A composition that contains, as active agent (A), an endocrine gland vascular endothelial growth factor (EG-VEGF) nucleic acid, polypeptide or antisense nucleic acid, antibody against EG-VEGF or its receptor (EG-VEGF-R), or EG-VEGF-R antisense nucleic acid, is useful for the treatment or prevention of endometrial diseases Independent claims are also included for the following: (1) method for detecting uterine receptivity by determining the amount of EG-VEGF polypeptide and/or nucleic acid, using the new composition; or (2) test system for identifying antagonists (B) of EG-VEGF-R.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-09-06T09:34:12.023084+00:00